Study

Alzheimer’s End-Of-Life Study

There's no single test to confirm Alzheimer's disease.

New Insights Through Imaging

The purpose of this end-of-life study is to evaluate the effectiveness of a new brain (PET) scan in accurately detecting Alzheimer’s disease. We hope that earlier, more accurate detection of Alzheimer’s disease will one day allow patients to confirm their diagnosis more easily, and then they can confidently begin new treatments that may delay—or possibly even reverse—the progression of the disease.

During the first part of the study, patient volunteers will get a PET scan using a new imaging procedure to look for specific proteins (tau) in the brain. Tau proteins are a biomarker—a sign that indicates Alzheimer’s disease.

When a person has passed away, their brain tissue is sent for analysis, to verify Alzheimer’s disease. The study may demonstrate the effectiveness of the new PET scan procedure in detecting— and possibly confirming—Alzheimer’s disease.

Who is eligible?

You may qualify for this study if:

You are 50+ years of age.
You have a projected life expectancy of less than or equal to 1 year.
You can lay down for a brain scan (PET scan).

Sign Up

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.